Whalen, Christin

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial

Konstantinopoulos, P. A., Barry, W. T., Birrer, M., Westin, S. N., Cadoo, K. A., Shapiro, G. I., Mayer, E. L., O'Cearbhaill, R. E., Coleman, R. L., Kochupurakkal, B., et al. (2019) · The Lancet Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 263

Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer

Penson, R. T., Ambrosio, A. J., Whalen, C. A., Krasner, C. N., Konstantinopoulos, P. A., Bradley, C., Matulonis, U. A., & Birrer, M. J. (2023) · The Oncologist

PARP inhibition in cancer therapyOvarian cancer diagnosis and treatment

Cited by 12